About Ipsen Limited
Ipsen Limited is the UK subsidiary of Ipsen, a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2014 in more than 115 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Ipsen's development strategy is supported by 3 franchises: endo-oncology, neurology, and uro-oncology. Ipsen's commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer and neuroendocrine tumours. The Ipsen Group also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totalled close to €187 million about 15% of Group sales). The Group has more than 4,500 employees.

Information on clinical trials can be found at http://www.clinicaltrials.gov/